Lyell Immunopharma Inc (LYEL)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
CEO:
Elizabeth Homans
Employees:
190
400 EAST JAMIE COURT, SUITE 301, SOUTH SAN FRANCISCO, CA 94080
650 695-0677

We are a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. We have assembled a world-class team, comprising some of the foremost scientific leaders in the fields of oncology and adoptive cell therapy (ACT), including Drs. Rick Klausner, Nick Restifo, Stan Riddell and Crystal Mackall, who have each interrogated and elucidated the mechanisms of T cell biology and its interactions with cancer for decades.

Data derived from most recent annual or quarterly report
Market Cap 1.652 Billion Shares Outstanding246.135 Million Avg 30-day Volume 1.287 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.2
Price to Revenue140.7969 Debt to Equity0.0 EBITDA-210.335 Million
Price to Book Value1.3993 Operating Margin-2603.1286 Enterprise Value348.068 Million
Current Ratio15.241 EPS Growth0 Quick Ratio14.953
1 Yr BETA 1.2412 52-week High/Low 19.84 / 3.57 Profit Margin-3006.6225
Operating Cash Flow Growth0.0 Altman Z-Score2.985 Free Cash Flow to Firm 0
Earnings Report2022-08-11

View recent insider trading info

Funds Holding LYEL (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding LYEL BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

RIEFLIN WILLIAM JL

  • Director
65,000 2022-06-08 1

BRAWLEY OTIS W

  • Director
65,000 2022-06-08 1

NELSEN ROBERT

  • Director
  • 10% Owner
36,477,716 2022-06-08 1

SEELY LYNN

  • Director
65,000 2022-06-08 1

FRIEDMAN CATHY

  • Director
401,370 2022-06-08 2

BISHOP HANS EDGAR

  • Director
4,605,234 2022-06-08 2

NABEL ELIZABETH G

  • Director
65,000 2022-06-08 1

ALBERTSON TINA M. CHIEF MEDICAL OFFICER

  • Officer
0 2022-03-23 1

TURNER HEATHER D CHIEF GENERAL COUNSEL

  • Officer
300,000 2022-03-16 1

HILL STEPHEN J. CHIEF TECHNICAL OPS. OFFICER

  • Officer
700,000 2022-03-16 1

NEWTON CHARLES W. CHIEF FINANCIAL OFFICER

  • Officer
500,000 2022-03-16 1

HOMANS ELIZABETH CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
1,479,500 2022-03-16 2

LEE GARY K. CHIEF SCIENTIFIC OFFICER

  • Officer
800,000 2022-02-11 2

GLAXOSMITHKLINE PLC

  • 10% Owner
30,253,189 2021-06-21 0

ARCH VENTURE PARTNERS IX, LLC

ARCH VENTURE FUND IX OVERAGE, L.P.

ARCH VENTURE FUND IX, L.P.

ARCH VENTURE PARTNERS IX OVERAGE, L.P.

ARCH VENTURE PARTNERS IX, L.P.

CRANDELL KEITH

BYBEE CLINTON

  • 10% Owner
36,412,716 2021-06-21 0

KLAUSNER RICHARD EXECUTIVE CHAIRMAN

  • Officer
  • Director
6,733,676 2021-06-21 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

KLAUSNER RICHARD - Director

2022-06-10 16:08:00 -0400 2022-06-08 A 65,000 a 65,000 direct

FRIEDMAN CATHY - Director

2022-06-10 16:09:41 -0400 2022-06-08 A 65,000 a 65,000 direct

BISHOP HANS EDGAR - Director

2022-06-10 16:11:35 -0400 2022-06-08 A 65,000 a 65,000 direct

BRAWLEY OTIS W - Director

2022-06-10 16:13:19 -0400 2022-06-08 A 65,000 a 65,000 direct

NABEL ELIZABETH G - Director

2022-06-10 16:14:50 -0400 2022-06-08 A 65,000 a 65,000 direct

SEELY LYNN - Director

2022-06-10 16:16:46 -0400 2022-06-08 A 65,000 a 65,000 direct

NELSEN ROBERT - Director - > 10% Owner

2022-06-10 16:18:43 -0400 2022-06-08 A 65,000 a 65,000 direct

RIEFLIN WILLIAM JL - Director

2022-06-10 16:20:27 -0400 2022-06-08 A 65,000 a 65,000 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
LYELL IMMUNOPHARMA INC LYEL 2022-06-30 22:15:03 UTC -7.7482 9.3182 15000
LYELL IMMUNOPHARMA INC LYEL 2022-06-30 21:45:03 UTC -7.7482 9.3182 15000
LYELL IMMUNOPHARMA INC LYEL 2022-06-30 21:15:03 UTC -7.7482 9.3182 15000
LYELL IMMUNOPHARMA INC LYEL 2022-06-30 20:45:03 UTC -7.1016 8.6716 15000
LYELL IMMUNOPHARMA INC LYEL 2022-06-30 20:15:04 UTC -7.1016 8.6716 15000
LYELL IMMUNOPHARMA INC LYEL 2022-06-30 19:45:03 UTC -7.1016 8.6716 15000
LYELL IMMUNOPHARMA INC LYEL 2022-06-30 19:15:03 UTC -7.1016 8.6716 15000
LYELL IMMUNOPHARMA INC LYEL 2022-06-30 18:45:04 UTC -7.0437 8.6137 10000
LYELL IMMUNOPHARMA INC LYEL 2022-06-30 18:15:04 UTC -7.0437 8.6137 10000
LYELL IMMUNOPHARMA INC LYEL 2022-06-30 17:45:03 UTC -7.0437 8.6137 25000
LYELL IMMUNOPHARMA INC LYEL 2022-06-30 17:15:03 UTC -7.0437 8.6137 25000
LYELL IMMUNOPHARMA INC LYEL 2022-06-30 16:45:04 UTC -7.9261 9.4961 25000
LYELL IMMUNOPHARMA INC LYEL 2022-06-30 16:15:03 UTC -7.9261 9.4961 25000
LYELL IMMUNOPHARMA INC LYEL 2022-06-30 15:45:03 UTC -7.9261 9.4961 25000
LYELL IMMUNOPHARMA INC LYEL 2022-06-30 15:15:03 UTC -7.9261 9.4961 25000
LYELL IMMUNOPHARMA INC LYEL 2022-06-30 14:45:03 UTC -7.9261 9.4961 20000
LYELL IMMUNOPHARMA INC LYEL 2022-06-30 14:15:03 UTC -7.9261 9.4961 20000
LYELL IMMUNOPHARMA INC LYEL 2022-06-30 13:45:03 UTC -7.9261 9.4961 20000
LYELL IMMUNOPHARMA INC LYEL 2022-06-30 13:15:03 UTC -7.9261 9.4961 20000
LYELL IMMUNOPHARMA INC LYEL 2022-06-30 12:45:03 UTC -7.9261 9.4961 20000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund LYEL -3800.0 shares, $-19190.0 2022-03-31 N-PORT

Elevate your investments